Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 3/20 | 0.48 |
| ▸ | CPS1 | P31327 | 1/20 | 0.48 |
| ▸ | CCKBR | P32239 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29897652 | 0.94 | MAPT (0.57) | MAPTTSHREPHX2SLC6A5RAB9A | |
| SCHEMBL968813 | 0.94 | MAPT (0.57) | MAPTTSHREPHX2SLC6A5RAB9A | |
| SCHEMBL643698 | 0.87 | CPS1 (0.60) | MAPTRAB9AKMT2ACPS1CCKBR | |
| SCHEMBL1424241 | 0.87 | CCKBR (0.56) | MAPTTSHRRAB9AKMT2ACNR1 | |
| SCHEMBL30791513 | 0.87 | CCKBR (0.56) | MAPTTSHRRAB9AKMT2ACNR1 | |
| SCHEMBL969401 | 0.86 | CCKBR (0.58) | MAPTTSHRRAB9AKMT2AMEN1 | |
| SCHEMBL1447765 | 0.84 | MAPT (0.56) | MAPTTSHRRAB9AKMT2ACNR1 | |
| SCHEMBL17400734 | 0.84 | MAPT (0.52) | MAPTTSHREPHX2KMT2AMEN1 | |
| SCHEMBL1447782 | 0.84 | HPGD (0.50) | MAPTSLC6A5RAB9AKMT2AMEN1 | |
| SCHEMBL16379735 | 0.83 | MAPT (0.57) | MAPTTSHREPHX2SLC6A5RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301928-A1 | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | CCNI, MKI67, TYMP | MAPT 3364/4885TSHR 3665/4885EPHX2 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.